Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-200 in HPV16+ HNSCC Patients With Positive TTMV-HPV DNA After Definitive Treatment
NCT06373380Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HB-200 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival up to 3 years. Started Apr 2024; status: active, not recruiting.
02
Drugs
HB-200
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06373380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373380.